文献速递糖尿病

糖尿病合并COVID-19患者出院与死亡预测因素:CORONADO全国研究更新结果

Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study.
PubMed 文献 · Diabetologia · 2021-02-17

CORONADO 是法国全国多中心研究,纳入 2796 例因 COVID-19 住院的糖尿病患者并随访 28 天。28 天内 50.2%(95%CI 48.3%, 52.1%)出院,20.6%(95%CI 19.2%, 22.2%)死亡。多变量模型显示年轻、常规二甲双胍治疗、入院时症状持续时间较长与出院正相关;微血管并发症史、常规抗凝治疗、入院时呼吸困难及较高 AST、白细胞计数和 CRP 与出院机会降低相关;死亡相关因素与出院因素镜像,胰岛素和他汀常规治疗也为不利因素。

要点

  • 糖尿病合并 COVID-19 住院患者 28 天出院率 50.2%,死亡率 20.6%。
  • 年轻、常规二甲双胍治疗、入院时症状持续时间较长与出院正相关。
  • 微血管并发症史、常规抗凝、入院呼吸困难及较高 AST、白细胞、CRP 与出院机会降低相关。

核心结论

  • 在因 COVID-19 住院的糖尿病患者中,研究确立了与出院和死亡相关的预后因素,可帮助临床医生在大流行期间进行判断。

研究设计与样本

  • CORONADO 为法国全国多中心研究,纳入 2020 年 3 月 10 日至 4 月 10 日入院、因 COVID-19 住院的糖尿病患者,随访 28 天,共 2796 例。

主要发现

  • 28 天内 1404 例(50.2%;95%CI 48.3%, 52.1%)出院,中位住院时间 9(5-14)天;577 例死亡(20.6%;95%CI 19.2%, 22.2%)。
  • 多变量模型中,年轻、常规二甲双胍治疗、入院时症状持续时间较长与出院正相关。
  • 微血管并发症史、常规抗凝治疗、入院时呼吸困难、较高 AST、白细胞计数和 CRP 与出院机会降低相关。
  • 与 28 天内死亡相关的因素与出院因素镜像,此外常规胰岛素和他汀治疗为不利因素。

临床怎么用

  • 可利用上述预后因素识别因 COVID-19 住院的糖尿病患者的出院机会与死亡风险。
  • 对存在微血管并发症史、入院呼吸困难或较高 AST、白细胞、CRP 的患者应加强关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). METHODS: The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. RESULTS: We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th-75th percentile) 28.4 (25.0-32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5-14) days, while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. CONCLUSIONS/INTERPRETATION: In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04324736.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wargny M, Potier L, Gourdy P, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia. 2021. PMID: 33599800. doi:10.1007/s00125-020-05351-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。